eye1

Sandoz shares positive results from MYLIGHT phase 3 study

Betsy Goodfellow | August 16, 2023 | News story | Research and Development |  Opthalmology, Sandoz, aflibercept, clinical trial, wet macular degeneration 

Sandoz has announced positive results from the phase 3 MYLIGHT confirmatory efficacy and safety study for its biosimilar aflibercept, for the treatment of patients with wet macular degeneration, part of the company’s efforts to address this area of unmet medical need.

The MYLIGHT study was part of a biosimilar development programme, with this section aiming to confirm the drug’s efficacy and safety, as well as meeting its primary endpoint demonstrating therapeutic equivalence in mean change of best corrected visual activity (BCVA) from baseline until week 6 between the biosimilar aflibercept and its reference biologic, Eylea.

The biosimilar’s safety, immunogenicity and pharmacokinetics show no clinical difference between the two products.

Advertisement

Claire D’Abreu-Hayling, chief scientific officer at Sandoz, commented: “This important milestone, confirming therapeutic equivalence of the biosimilar aflibercept with the reference biologic, takes us one step closer to providing patients with a key treatment in an area of high unmet need within ophthalmology. It also underscores our ability to provide high-quality, affordable biologics to individuals to help the treatment of their disease, and highlights the rich Sandoz pipeline of biologics.”

The company plans to file for regulatory approval for its biosimilar in the US and EU within the next few months.

Betsy Goodfellow

Related Content

SMC accepts atogepant for acute migraine treatment in Scotland

The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the …

Amphista doses first patient in AML trial of protein degrader

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Tridem begins phase Ib trial of Parkinson’s disease vaccine

Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

The Gateway to Local Adoption Series

Latest content